Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, discuses an evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic needle biopsy specimens. (Abstract 4)
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary ...
Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplati...
Joshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new ...
Sumanta K. Pal, MD, of the City of Hope, summarizes a session he co-chaired on the opportunities and challenges in systemic therapy for advanced renal cancer, including imaging as a b...
Emma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiot...